Illustrative image of pineapple slices with leaves (Tim UR; iStock by Getty Images)
MediWound, a biotech firm that makes burn and wound treatments, said Monday it will start a clinical trial in three US medical centers of a new drug candidate to treat non-melanoma skin cancer.
The phase I/II clinical trial , which is scheduled to start in the second quarter of the year, will study the safety, tolerability and efficacy of the drug product candidate MWPC005 for the non-invasive treatment of basal cell carcinoma (BCC), a non-melanoma skin cancer that arises from the basal layer of epidermis and its appendages. Results of the trial, which will evaluate the drug in patients with the disease, are expected by the end of the year, the company said in a statement, along with the results of a phase II trial of the drug candidate that will be conducted in parallel at the Soroka Medical Center in Israel.
Noname Security launches from stealth with $25 million to help secure APIs. The continued digital transformation of businesses has left them exposed to threats and attack – something Noname hopes to stop. Read more Tel Aviv skyline. Photo: Bloomberg
Covid-19 was one of the biomed industry’s finest hours, says Israeli Silicon Valley veteran. Aya Jakobovits, a trailblazer in the biomed sector who is participating in J-Ventures’ annual investor’s conference, speaks of how the coronavirus vaccines showcased the depth of new technology. Read more
Artlist to add new features with acquisition of Motion Array for $65 million. With focus on video content for creators, the Israeli company says it is ready to give Getty and Shutterstock a run for their money. Read more
Share:
YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid
® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab .
MediWound Ltd.December 14, 2020 GMT
YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.
Illustrative image of sliced pineapple (Anusorn Sutapan; iStock by Getty Images)
“GAG, through its life sciences arm – Gaelan Medical Trade LLC, has extensive knowledge and experience in treating wounds, and holds substantial relationships with important clinical institutions in the UAE. We believe that together with GAG we can create new opportunities for NexoBrid across the region, providing a new paradigm for burn experts in treating severe burns, which can improve the lives of patients and healthcare quality they receive,” Malka said.
Ghassan Aboud Group (GAG) is an international conglomerate that operates in a variety of sectors including automotive, logistics, media, hospitality, real estate, retail, and catering. Headquartered in the United Arab Emirates, GAG also has offices in Australia, Belgium, China, Jordan and Turkey.